Mohapatra Shyam S
Division of Allergy and Immunology-JMC Airway Disease Research Center, Department of Internal Medicine, University of South Florida and VA Hospital, Tampa, FL 33612, USA.
Can J Physiol Pharmacol. 2007 Jul;85(7):754-9. doi: 10.1139/Y07-066.
Atrial natriuretic peptide (ANP), the C-terminal peptide comprising residues 99-126 of the pro-ANP hormone, has been studied for 3 decades for its cardiovascular effects. Recent reports suggest that it plays a significant role in modulation of the immune system. Immune cells, including macrophages, dendritic cells, and T lymphocytes, express receptors for ANP. ANP plays a significant role in shaping the early immune response to environmental antigens and may play a critical role in the interaction between cells of the innate and adaptive immune systems; it also appears to be involved in polarizing the immune response to allergens. Thus, ability to alter the magnitude of natriuretic peptide receptor A (NPRA) signaling could be exploited to develop therapeutics for several allergic diseases, including asthma. This report will review and critically evaluate the role of the ANP pathway in asthma and inflammation.
心房利钠肽（ANP）是前ANP激素第99 - 126位残基组成的C末端肽，其心血管效应已被研究了30年。最近的报告表明，它在免疫系统调节中发挥重要作用。免疫细胞，包括巨噬细胞、树突状细胞和T淋巴细胞，表达ANP受体。ANP在塑造对环境抗原的早期免疫反应中起重要作用，可能在先天和适应性免疫系统细胞之间的相互作用中起关键作用；它似乎也参与使免疫反应偏向过敏原。因此，改变利钠肽受体A（NPRA）信号强度的能力可用于开发针对包括哮喘在内的几种过敏性疾病的治疗方法。本报告将回顾并批判性地评估ANP途径在哮喘和炎症中的作用。
